• Top Scientists Cautious About Curing Cancer With Immunotherapy

    STAT | There's been a lot of excitement about immunotherapy as a tool to treat cancer. But top experts on Sunday struck an unexpected note of caution.

    Sep 26, 2016

  • New Genomics Pipeline Combines AWS, Local HPC, and Supercomputing

    HPCwire | Declining DNA sequencing costs and the rush to do whole genome sequencing (WGS) of large cohort populations presents an infrastructure challenge that some researchers are solving with a hybrid approach.

    Sep 23, 2016

  • When “Actionable” Genomic Sequencing Results Cannot Be Acted Upon

    JAMA Oncology | Brian J. Zikmund-Fisher recounts an interaction he had with a participant involved in genomic sequencing, in which the term “actionable” led to false hope and dashed expectations.

    Sep 23, 2016

  • Gilead Allergan Seen Trailing Intercept In Ongoing NASH Battle

    Investor's Business Daily | Gilead is trailing Intercept in the battle against NASH, Credit Suisse analyst Alethia Young said Thursday, two days after Botox maker Allergan jumped in.

    Sep 23, 2016

  • Chan Zuckerberg Initiative Lays Out Plan For Funding Disease Research

    Bio-IT World | The Chan Zuckerberg Initiative took to Facebook Live yesterday to lay out their plan of funding the Initiative’s first project. The project, a Biohub located in San Francisco, will combine the knowledge of renowned scientists and engineers in the pursuit of curing disease. 

    Sep 22, 2016

  • Monsanto Licenses CRISPR Technology To Modify Crops

    STAT | Agriculture giant Monsanto has licensed CRISPR-Cas9 genome-editing technology from the Broad Institute to develop modified seeds.

    Sep 22, 2016

  • Getting Exascale Right, Not First

    TOP500 | The path to exascale computing hasn't been an easy one. It has had to face a daunting set of challenges in energy efficiency, application parallelism, and system reliability, just to name a few. The difficulties in bringing the hardware and software up to this level is considerable, but there is a more fundamental challenge at the heart of exascale: doing the necessary work of building an ecosystem that will last for a decade or more, not just for a handful stunt machines.

    Sep 21, 2016

  • Taking Care Of Our Own: HR In The Age Of Genomics

    Bio-IT World | As far as their employees are concerned, who among these life-science players are putting their money where their mouths are? The search has been on at Bio-IT World for those organizations who are taking the logical step of subsidizing the sequencing their own employees' genomes and the clinical interpretation thereof.

    Sep 21, 2016